Biomarin Pharmaceutical (BMRN) EBT: 2009-2025
Historic EBT for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to -$26.3 million.
- Biomarin Pharmaceutical's EBT fell 119.58% to -$26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $679.3 million, marking a year-over-year increase of 73.53%. This contributed to the annual value of $541.8 million for FY2024, which is 187.31% up from last year.
- Latest data reveals that Biomarin Pharmaceutical reported EBT of -$26.3 million as of Q3 2025, which was down 108.84% from $297.9 million recorded in Q2 2025.
- In the past 5 years, Biomarin Pharmaceutical's EBT ranged from a high of $297.9 million in Q2 2025 and a low of -$66.6 million during Q4 2021.
- In the last 3 years, Biomarin Pharmaceutical's EBT had a median value of $105.5 million in 2024 and averaged $112.7 million.
- In the last 5 years, Biomarin Pharmaceutical's EBT skyrocketed by 2,288.50% in 2023 and then plummeted by 119.58% in 2025.
- Quarterly analysis of 5 years shows Biomarin Pharmaceutical's EBT stood at -$66.6 million in 2021, then surged by 73.63% to -$17.6 million in 2022, then surged by 210.08% to $19.3 million in 2023, then soared by 777.73% to $169.6 million in 2024, then crashed by 119.58% to -$26.3 million in 2025.
- Its EBT was -$26.3 million in Q3 2025, compared to $297.9 million in Q2 2025 and $238.1 million in Q1 2025.